Novartis CEO and incoming PhRMA board chair Vas Narasimhan says nullifying the Inflation Reduction Act’s nine-year timeline for small molecules tops his agenda.
‘Known unknowns’ make new pricing law a wild card for drug companies
The Inflation Reduction Act is the drug industry’s new talking point. Companies are raising awareness of the law’s unintended consequences, while reassuring investors that they can manage through the risk.
‘We’re still here’: U.S., global drug markets show robust recovery
Highlights from Marc Iskowitz’s weekly MM+M franchise, and a year-end salute to the professionals who work on the commercial end of the healthcare business.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix